Kiora Pharmaceuticals (KPRX) Interest Expenses (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Interest Expenses came in at $24154.0 in Q1 2026, up 90.08% YoY from $12707.0 in Q1 2025, and up 2415300.0% on a QoQ basis from $1.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Interest Expenses (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 12 years of Interest Expenses data on file, last reported at $24154.0 in Q1 2026.
- Quarterly Interest Expenses rose 90.08% year-over-year to $24154.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24154.0 (up 90.08% YoY) and the FY2025 annual result came in at $16.9 million, up 28.34% from the prior year.
- Interest Expenses improved to $24154.0 in Q1 2026, from $1.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $33.0 million in Q4 2023 to a low of -$114650.0 in Q4 2022.
- A 5-year average of $2.7 million and a median of $33000.0 in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses surged 28905.78% — and 2025, when it sank 100.0%.
- Tracing KPRX's Interest Expenses over 5 years: stood at -$114650.0 in 2022, then surged by 28905.78% to $33.0 million in 2023, then tumbled by 60.21% to $13.1 million in 2024, then slumped by 100.0% to $1.0 in 2025, then jumped by 2415300.0% to $24154.0 in 2026.
- The last three Interest Expenses figures came in at $24154.0 (Q1 2026), $1.0 (Q4 2025), and $33000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 352,054.00 |
| Jun 30, 2026 | 352,054.00 |
| Mar 31, 2026 | 24,154.00 |
| Mar 31, 2026 | 24,154.00 |
| Dec 31, 2025 | 1.00 |
| Dec 31, 2025 | 1.00 |
| Sep 30, 2025 | 33,000.00 |
| Sep 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 39,215.00 |
| Jun 30, 2025 | 39,215.00 |
| Mar 31, 2025 | 12,707.00 |
| Mar 31, 2025 | 12,707.00 |
| Dec 31, 2024 | 13.14 Mn |
| Dec 31, 2024 | 13.14 Mn |
| Sep 30, 2024 | 9,318.00 |
| Sep 30, 2024 | 9,318.00 |
| Jun 30, 2024 | 92,835.00 |
| Jun 30, 2024 | 92,835.00 |
| Mar 31, 2024 | 12,412.00 |
| Mar 31, 2024 | 12,412.00 |